

Best-value biological (BVB) medicines / Best-value medicines (BVM) 2026

The HSE-Medicines Management Programme has identified the following medicines for which it may conduct a best-value biological (BVB) medicine or best-value medicine (BVM) process in 2026:

Biological Medicines

- Adalimumab (L04AB04)
- Denosumab (M05BX04)
- Eculizumab (L04AJ01)
- Etanercept (L04AB01)
- Filgrastim (L03AA02)
- Follitropin alfa (G03GA05)
- Golimumab (L04AB06)
- Lipegfilgrastim (L03AA14)
- Liraglutide (A10BJ02)
- Pegfilgrastim (L03AA13)
- Somatropin (H01AC01)
- Teriparatide (H05AA02)
- Tocilizumab (L04AC07)
- Ustekinumab (L04AC05)

Non-Biological Medicines

- Bicalutamide (L02BB03)
- Fulvestrant (L02BA03)
- Glatiramer (L03AX13)